Spirocyclic CETP inhibitors

US9717714B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Debra L. Ondeyka · Fanwood, US
• Xiaoxia Qian · New York, US
• Petr Vachal · Summit, US
• Sriram Tyagarajan · Edison, US
• Cameron Smith · Lawrenceville, US
• Hong Li · Edison, US
• Jianming Bao · Scotch Plains, US

Key dates

• Filing date: Dec 17, 2013
• Grant date: Aug 1, 2017
• Expiry date: Dec 17, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis.